Vaccine description | |
---|---|
Target disease | SARS-CoV-2 |
Type | DNA vaccination |
Clinical data | |
Other names | Inovio COVID-19 Vaccine |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
INO-4800 is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.
In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.[1][2] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.[3] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.[4]
Inovio is collaborating with Beijing Advaccine Biotechnology Co., a Chinese biotech firm,[2] in order to speed its acceptance by regulatory authorities in China , with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.[5][6] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.[2] In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.[5][7]
In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea , to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.[8] The trial is funded by the Coalition for Epidemic Preparedness Innovations and supported by the Korea Centers for Disease Control and Prevention and the Korea National Institute of Health.[8]